GlassScriptPhysician profile
Samir Panvelker
NPI 1194145250
$752.85
in general payments reported to CMS, 2019-2025
12 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $24.32 · 2023: $185 · 2024: $393 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $728.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $258.96 | 2024-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $130.07 | 2023-2024 | Mounjaro, Trulicity, Zepbound |
| Dexcom, INC. | $66.62 | 2023-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $62.00 | 2024-2025 | Tepezza |
| Abbott Laboratories | $48.65 | 2022-2023 | Freestyle Libre 3 |
| Radius Health, INC. | $43.44 | 2023 | Tymlos |
| Sanofi-Aventis U.S. LLC | $34.80 | 2024 | |
| Glaxosmithkline, LLC. | $31.72 | 2024 | Arexvy, Trelegy Ellipta |
| Tandem Diabetes Care, INC. | $22.90 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Novartis Pharmaceuticals Corporation | $21.59 | 2023 | |
| Ardelyx, INC. | $18.17 | 2025 | Ibsrela |
| Cequr Corporation | $13.93 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Panvelker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.